Selleck Chemicals supplies over 3,000 inhibitors used in the study of cell signaling pathways. We actively tracks the latest science so our customers can rely on us to be the leading supplier of the newest inhibitors.
Company WebsiteMapatumumab (Anti-TNFRSF10A / TRAILR1 / CD261) is a fully human IgG1 agonistic monoclonal antibody that targets tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) with apoptosis promoting and potential antitumor activities. MW : 145.5 KD.
More Information Supplier PageMapatumumab (Anti-TNFRSF10A / TRAILR1 / CD261) is a fully human IgG1 agonistic monoclonal antibody that targets tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) with apoptosis promoting and potential antitumor activities. MW : 145.5 KD.
More Information Supplier PageMapatumumab (Anti-TNFRSF10A / TRAILR1 / CD261) is a fully human IgG1 agonistic monoclonal antibody that targets tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) with apoptosis promoting and potential antitumor activities. MW : 145.5 KD.
More Information Supplier PageA unique collection of 258 small molecule inhibitors used for MAPK signaling research.
More Information Supplier PageA unique collection of 258 small molecule inhibitors used for MAPK signaling research.
More Information Supplier PageMaprotiline HCl is a selective noradrenalin re-uptake inhibitor, used in the treatment of depression.
More Information Supplier PageMaprotiline HCl is a selective noradrenalin re-uptake inhibitor, used in the treatment of depression.
More Information Supplier PageMarasmius Extract is extracted from Marasmius androsaceus, which is the only analgesic medicinal fungi that can treat various types of neuralgia, the mechanism of its treatment of migraine has been paid more and more attention.
More Information Supplier PageMaraviroc is a CCR5 antagonist for MIP-1α, MIP-1β and RANTES with IC50 of 3.3 nM, 7.2 nM and 5.2 nM in cell-free assays, respectively. Maraviroc is used in the treatment of HIV infection.
More Information Supplier PageMaraviroc is a CCR5 antagonist for MIP-1α, MIP-1β and RANTES with IC50 of 3.3 nM, 7.2 nM and 5.2 nM in cell-free assays, respectively. Maraviroc is used in the treatment of HIV infection.
More Information Supplier PageMaraviroc is a CCR5 antagonist for MIP-1α, MIP-1β and RANTES with IC50 of 3.3 nM, 7.2 nM and 5.2 nM in cell-free assays, respectively. Maraviroc is used in the treatment of HIV infection.
More Information Supplier PageMaraviroc is a CCR5 antagonist for MIP-1α, MIP-1β and RANTES with IC50 of 3.3 nM, 7.2 nM and 5.2 nM in cell-free assays, respectively. Maraviroc is used in the treatment of HIV infection.
More Information Supplier PageMaraviroc is a CCR5 antagonist for MIP-1α, MIP-1β and RANTES with IC50 of 3.3 nM, 7.2 nM and 5.2 nM in cell-free assays, respectively. Maraviroc is used in the treatment of HIV infection.
More Information Supplier PageMarbofloxacin is a potent antibiotic inhibiting bacterial DNA replication.
More Information Supplier PageMardepodect (PF-2545920) is a potent and selective PDE10A inhibitor with IC50 of 0.37 nM, with >1000-fold selectivity over the PDE.
More Information Supplier PageMardepodect (PF-2545920) is a potent and selective PDE10A inhibitor with IC50 of 0.37 nM, with >1000-fold selectivity over the PDE.
More Information Supplier PageMardepodect (PF-2545920) is a potent and selective PDE10A inhibitor with IC50 of 0.37 nM, with >1000-fold selectivity over the PDE.
More Information Supplier PageMardepodect (PF-2545920) is a potent and selective PDE10A inhibitor with IC50 of 0.37 nM, with >1000-fold selectivity over the PDE.
More Information Supplier PageMardepodect (PF-2545920) is a potent and selective PDE10A inhibitor with IC50 of 0.37 nM, with >1000-fold selectivity over the PDE.
More Information Supplier PageMargetuximab (Anti-ERBB2 / HER2 / CD340) is a Fc-domain optimized IgG monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2) with potential immunomodulating and antineoplastic activities. MW: 146.1 KD.
More Information Supplier PageMargetuximab (Anti-ERBB2 / HER2 / CD340) is a Fc-domain optimized IgG monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2) with potential immunomodulating and antineoplastic activities. MW: 146.1 KD.
More Information Supplier PageMargetuximab (Anti-ERBB2 / HER2 / CD340) is a Fc-domain optimized IgG monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2) with potential immunomodulating and antineoplastic activities. MW: 146.1 KD.
More Information Supplier PageMarimastat (BB-2516, TA2516) is a broad spectrum matrix metalloprotease (MMP) inhibitor for MMP-9, MMP-1, MMP-2, MMP-14 and MMP-7 with IC50 of 3 nM, 5 nM, 6 nM, 9 nM and 13 nM, respectively. Phase 3.
More Information Supplier PageMarimastat (BB-2516, TA2516) is a broad spectrum matrix metalloprotease (MMP) inhibitor for MMP-9, MMP-1, MMP-2, MMP-14 and MMP-7 with IC50 of 3 nM, 5 nM, 6 nM, 9 nM and 13 nM, respectively. Phase 3.
More Information Supplier PageMarimastat (BB-2516, TA2516) is a broad spectrum matrix metalloprotease (MMP) inhibitor for MMP-9, MMP-1, MMP-2, MMP-14 and MMP-7 with IC50 of 3 nM, 5 nM, 6 nM, 9 nM and 13 nM, respectively. Phase 3.
More Information Supplier PageMarimastat (BB-2516, TA2516) is a broad spectrum matrix metalloprotease (MMP) inhibitor for MMP-9, MMP-1, MMP-2, MMP-14 and MMP-7 with IC50 of 3 nM, 5 nM, 6 nM, 9 nM and 13 nM, respectively. Phase 3.
More Information Supplier PageMarinopyrrole A (Maritoclax) is a selective Mcl-1 antagonist. It binds to Mcl-1, but not Bcl-XL, and targets Mcl-1 for proteasomal degradation. Maritoclax disrupts the interaction between Bim and Mcl-1 with an IC50 of 10.1 μM.
More Information Supplier PageMarizomib (Salinosporamide A) is a novel marine derived proteasome inhibitor which inhibits CT-L β5, C-L β1, and T-L β2 proteasome activities in human erythrocyte-derived 20S proteasomes with IC50 of 3.5 nM, 430 nM, 28 nM.
More Information Supplier PageMarizomib (Salinosporamide A) is a novel marine derived proteasome inhibitor which inhibits CT-L β5, C-L β1, and T-L β2 proteasome activities in human erythrocyte-derived 20S proteasomes with IC50 of 3.5 nM, 430 nM, 28 nM.
More Information Supplier PageMARK4 inhibitor 1 is a potent microtubule affinity-regulating kinase 4 (MARK4) inhibitor, with an IC50 of 1.54 μM for MARK4 inhibition assay.
More Information Supplier PageMARK4 inhibitor 1 is a potent microtubule affinity-regulating kinase 4 (MARK4) inhibitor, with an IC50 of 1.54 μM for MARK4 inhibition assay.
More Information Supplier PageMarlea platanifolia Extract is extracted from Marlea platanifoli that exhibits anti-inflammatory and analgesic activities.
More Information Supplier PageMarmesin (S-(+)-Marmesin, (+)-Marmesin, (S)-Marmesin) is a natural coumarin with COX-2 and 5-LOX dual inhibitory activity.
More Information Supplier PageMaropitant citrate is a novel neurokinin type-1 (NK1) receptor antagonist with anti-inflammatory and analgesic properties.
More Information Supplier PageMaropitant citrate is a novel neurokinin type-1 (NK1) receptor antagonist with anti-inflammatory and analgesic properties.
More Information Supplier PageMarstacimab (Anti-TFPI) is a monoclonal antibody targeting tissue factor pathway inhibitor (TFPI). It can be used for the research of hemophilia. MW :142.94 KD.
More Information Supplier PageMarstacimab (Anti-TFPI) is a monoclonal antibody targeting tissue factor pathway inhibitor (TFPI). It can be used for the research of hemophilia. MW :142.94 KD.
More Information Supplier PageMarstacimab (Anti-TFPI) is a monoclonal antibody targeting tissue factor pathway inhibitor (TFPI). It can be used for the research of hemophilia. MW :142.94 KD.
More Information Supplier PageMasitinib is a novel inhibitor for Kit (c-Kit) and PDGFRα/β with IC50 of 200 nM and 540 nM/800 nM, weak inhibition to ABL and c-Fms. Phase 3.
More Information Supplier PageMasitinib is a novel inhibitor for Kit (c-Kit) and PDGFRα/β with IC50 of 200 nM and 540 nM/800 nM, weak inhibition to ABL and c-Fms. Phase 3.
More Information Supplier PageMasitinib is a novel inhibitor for Kit (c-Kit) and PDGFRα/β with IC50 of 200 nM and 540 nM/800 nM, weak inhibition to ABL and c-Fms. Phase 3.
More Information Supplier PageMasitinib mesylate (AB-1010 mesylate) is a potent, orally bioavailable, and selective inhibitor of c-Kit with IC50 of 200 nM for human recombinant c-Kit, also inhibits PDGFRα/β with IC50s of 540/800 nM, Lyn with IC50 of 510 nM for LynB, and, to a lesser extent, FGFR3 and FAK.
More Information Supplier PageMaslinic Acid (Crategolic Acid, 2α-Hydroxyoleanoic Acid), a Natural Triterpene, exerts a wide range of biological activities, i.e. antitumor, antidiabetic, antioxidant, cardioprotective, neuroprotective, antiparasitic and growth-stimulating. MA significantly suppresses the DNA-binding activity of NF-κB p65 in LPS-induced RAW 264.7 cells.
More Information Supplier PageMassa Medicata Fermentata Extract is extracted from Massa Medicata Fermentata.
More Information Supplier PageMasson Pine Needle Extract is extracted from the needles of Pinus massoniana, which aids in gastrointestinal disorders and oxidative stress.
More Information Supplier PageMatcha Powder is extracted from Matcha, which has a high content of antioxidant and anti-inflammatory substances.
More Information Supplier PageMatuzumab (anti-ERBB1/ EGFR / HER1) is a humanized anti-epidermal growth factor receptor (EGFR) monoclonal antibody that blocks EGFR activation, downstream signalling, and inhibits tumor growth. MW: 145.9 KD.
More Information Supplier PageMatuzumab (anti-ERBB1/ EGFR / HER1) is a humanized anti-epidermal growth factor receptor (EGFR) monoclonal antibody that blocks EGFR activation, downstream signalling, and inhibits tumor growth. MW: 145.9 KD.
More Information Supplier PageMatuzumab (anti-ERBB1/ EGFR / HER1) is a humanized anti-epidermal growth factor receptor (EGFR) monoclonal antibody that blocks EGFR activation, downstream signalling, and inhibits tumor growth. MW: 145.9 KD.
More Information Supplier PageMavacamten (MYK-461, SAR439152) is a small-molecule modulator of cardiac myosin that targets the underlying sarcomere hypercontractility of hypertrophic cardiomyopathy (HCM), one of the most prevalent heritable cardiovascular disorders.
More Information Supplier Page
